Skip to main content
OpenTrials
Completed

NCT Number: NCT00790686

Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter

TOTEME offers to treat certain chronic strictures of the ureter with MEMOKATH 051 to assess its effectiveness, tolerance and mean durability during a 3 years follow up period.

Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy. After this procedure, the patients will have medical examinations, blood exams, radiography and renal sonography during 3 years. If a problem of tolerance or effectiveness is diagnosed, the ureteral stent MEMOKATH 051 will be changed or replaced with a double J stent.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Urology, University Hospital, Bordeaux, Bordeaux, France

Loading trial locations.

About this study

Introduction:

The chronic strictures of the ureter are usually treated by double J stents. They allow the emptying of the kidney and avoid the deterioration of renal function. Unfortunately, double J stents have to be replaced every 6 month and are at the origin of irritative lower urinary tract symptoms and lumbar pain which corrupt the quality of life of the patients.

Ureteral stricture could also be treated with MEMOKATH 051. These new ureteral stents seem not to require iterative changes and also not to cause irritative symptoms and lumbar pain. MEMOKATH 051 could therefore allow to reduce the number of changes and to ameliorate the quality of life of the patients.

Main objective:

Main objective is to assess effectiveness and tolerance of the MEMOKATH ® 051 in the treatment of chronic strictures of the ureter.

Resume:

Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.

After this procedure, the patients will have medical examination, blood exams, radiography and renal sonography at 1 month, 3 month and every 6 month during a 3 years follow up period.

If a problem of tolerance or effectiveness is diagnosed, the ureteral stent MEMOKATH 051 will be changed or replaced with a double J stent and an adverse event will be declared.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-year-old or superior
  • Chronic stenosis of the ureter treated by placement of a ureteral endoprosthesis for more than six months;
  • No possibility for surgical or endoscopic treatment of the ureteral stricture
  • Free Consent, dated and signed by the patient
  • Affiliated Subject of a regime of French national health and pensions organization.

Exclusion criteria

  • Age under 18 year old
  • Pregnant or nursing Women
  • Patient having a life expectancy of less than 1 year
  • Patient having unique kidney
  • Patient having severe renal insufficiency (creatinin clearance under 30 ml/min)
  • Possible surgical or endoscopic treatment of ureteral stricture
  • Repeated urinary tract stones
  • Urothelial tumor of the bladder
  • Retro peritoneal fibrosis in the course of evolution
  • Complications of double J stents requiring more thanks a lot every 6 months
  • Against anaesthetic indication
  • Lithiasic inlay probe Double J with obstruction within 6 months
  • Persons put under maintenance of justice
  • Persons in inability to understand the sequence of try

Treatment and study plan

Insertion of Memokath 051

Procedure

Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.

Primary outcomes

  1. Average durability of the stent MEMOKATH ® 051

    Time frame: 3 years

Secondary outcomes

  1. Proportion of ureteral stent MEMOKATH ® 051 positioning failure

    Time frame: 3 years

  2. Average quality of life of the patients measured by auto-questionary

    Time frame: 3 years

  3. Proportion of patients to which the ureteral stent was definitely taken away

    Time frame: 3 years

  4. Expense of hospitalizations for replacement of the ureteral stent

    Time frame: 3 years

  5. Proportion of replacement of the ureteral stent

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Study of Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in the Treatment of Chronic Strictures of the Ureter

Acronym: TOTEME

Important dates

Study start
2008
Primary completion
2013
Study completion
2013
First posted
Nov 13, 2008
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.